

Institute NEOMED

POWERING CANADIAN INNOVATION WITH DRUG DISCOVERY EXPERTISE, GLOBAL NETWORKS & WORLD-CLASS R&D FACILITIES

ABOUT THE NEOMED INSTITUTE

The NEOMED Institute was created in 2012 with the support of AstraZeneca, Pfizer Canada and the Government of Quebec. AstraZeneca donated its Montreal R&D site, a state-of-the-art research facility equipped with laboratories and highly sophisticated equipment, and three therapeutic programs. In 2014, NEOMED received support from the Canadian government when it was named a Centre of Excellence in Commercialization and Research (CECR) and in 2015, the NEOMED Institute acquired the GlaxoSmithKline Biologics and Vaccines R&D site as well as an experienced team providing immune-monitoring support for clinical trials (NEOMED Labs).

The NEOMED institute is a successful and innovative Canadian not-for-profit R&D organization whose mission is to enable and accelerate the commercialization of Canadian life science discoveries. To accomplish this mission NEOMED Institute operates two complementary and integrated divisions:

NEOMED Therapeutics in-licenses promising scientific discoveries from academic centers and research institutes and funds and develops these programs to stages that are attractive for partnering or stand-alone financing. All proceeds from successful out-licensing and exits are re-invested in new pipeline projects.

NEOMED Innovation Center operates a world-class life sciences ecosystem in Montreal, Quebec, that was created as an enabling environment for biotechnology and contract research organizations to establish, grow and prosper. Today the NEOMED Innovation Centre hosts 30 life sciences companies employing over 350 people who operate in two state-of-the-art R&D centres comprising over 200,000 sq. ft. of fully equipped laboratories.

The NEOMED Institute is funded by pharmaceutical partners, the Ministère de l'Économie de la Science et de l'Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada as well as from revenue generated from the out-licensing/sale of our research pipeline projects and the operation of our facilities.



The Saint-Laurent Technoparc Montreal facility is dedicated to the development of small molecule therapeutics.



The Laval Cité de la Biotech Montreal facility is dedicated to the development of biologics and vaccines.

NEOMED INSTITUTE - KEY FACTS

10

In-licensed therapeutic programs

2

Partnered programs



2 world-class R&D facilities

housing 30 resident

companies employing more than

350 people

5

Pharma Partners



1

Completed Phase 2 POC clinical trial (NEO6860)



1

Successful CRO

3

Declared clinical development candidates

1


Expansion plan (Saint-Laurent Technoparc Montreal)

EPIGENE
THERAPEUTICS INC

1

Spinout

NEOMED THERAPEUTICS - PIPELINE



NEOMED THERAPEUTICS - R&D PARTNERSHIPS

NEOMED Therapeutics is actively scouting and encouraging proposals on **innovative therapeutic targets** from academic/ research centres and biotechs to advance these programs up to human proof of concept.

What are we seeking ?

- Validated targets backed by strong scientific hypotheses
- Potential for small molecule therapeutics
- Open to any therapeutic indication
- Clear therapeutic benefit over standard-of-care treatment
- Existing or potential for strong IP protection
- Clear differentiation factors from competitive products and/or approaches
- Potential to establish POC in modest Phase 2 study

NEOMED THERAPEUTICS - LICENSING

NEOMED Therapeutics is actively looking to progress certain programs through either:

- A traditional licensing transaction
- A co-funding/co-development partnership with an option/first right on the program; or,
- The creation of a standalone NewCo or bundling into another start-up/NewCo's portfolio

NEOMED INNOVATION CENTER - WHERE SCIENTIFIC INNOVATION AND COLLABORATION GO HAND-IN-HAND

NEOMED's Innovation Center, St-Laurent specializes in small molecule drug discovery. It offers fully-equipped medicinal chemistry and biology laboratories, capacity for 105 chemistry hoods, an on-site vivarium and specialized drug discovery equipment. Facing major demand from biotechnology companies and CROs wishing to join our ecosystem, NEOMED is planning to expand its St-Laurent Technoparc Montreal site by fall 2019. This expansion will allow NEOMED to host more than 200 scientists and technicians.

NEOMED's Innovation Center, Laval is equipped to support biologics and vaccines research. It is home to 9 companies including NEOMED Labs, a CRO offering high-quality clinical immunology laboratory services and GCLP-compliant immunomonitoring activities to support Phase I to Phase IV vaccine clinical trials. Services also include cell culture, molecular biology and process development.



Building on the right is the expansion project
Delivery Fall, 2019
Taking reservations for 2019 occupancy

CONTACT INFO :

For more information, please visit our website **www.neomed.ca**

To submit a project proposal: Complete the form on our website (<http://neomed.ca/en/propose-a-project/form/>) or contact **Patricia Escoffier**, Director Scientific Affairs at **pescoffier@neomed.ca**

Business Development: **Daniel Böck**, VP Business Development, at **dbock@neomed.ca**

NEOMED Innovation Center: **Pierre-Yves Desbiens**, Chief Operating Officer, at **pydesbiens@neomed.ca**